ReviewPharmaceutics2025
The Potential of Amphiphilic Cyclodextrins as Carriers for Therapeutic Purposes: A Short Overview.
Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cyclodextrin-Based Delivery Systems in Cosmeceuticals: Current Advances and Future Perspectives.Biomolecules · 2026Review
- β-Cyclodextrin Inclusion Complexes ofPharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclodextrins, since their discovery in the late 19th century, have gained tremendous interest in biomedical research, beginning with their recognition as safe pharmaceutical excipients, and continuing with exploiting their potential for enhancing the therapeutic response of active pharmaceutical ingredients, and also to be used as drugs for specific medical purposes. This review presents an integrative perspective on amphiphilic cyclodextrins, the manuscript being divided into two parts, one devoted to the properties of amphiphilic cyclodextrins, while the second one is dedicated to their biomedical applications, with an emphasis on cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.